265 related articles for article (PubMed ID: 27755245)
1. Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection.
Deidda M; Madonna R; Mango R; Pagliaro P; Bassareo PP; Cugusi L; Romano S; Penco M; Romeo F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e76-e83. PubMed ID: 27755245
[TBL] [Abstract][Full Text] [Related]
2. Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection.
Deidda M; Madonna R; Mango R; Pagliaro P; Bassareo PP; Cugusi L; Romano S; Penco M; Romeo F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S76-83. PubMed ID: 27183528
[TBL] [Abstract][Full Text] [Related]
3. Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection.
Deidda M; Mercurio V; Cuomo A; Noto A; Mercuro G; Cadeddu Dessalvi C
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590338
[TBL] [Abstract][Full Text] [Related]
4. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e64-e75. PubMed ID: 27755244
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of cytotoxic drugs.
Schimmel KJ; Richel DJ; van den Brink RB; Guchelaar HJ
Cancer Treat Rev; 2004 Apr; 30(2):181-91. PubMed ID: 15023436
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function.
De Angelis A; Piegari E; Cappetta D; Marino L; Filippelli A; Berrino L; Ferreira-Martins J; Zheng H; Hosoda T; Rota M; Urbanek K; Kajstura J; Leri A; Rossi F; Anversa P
Circulation; 2010 Jan; 121(2):276-92. PubMed ID: 20038740
[TBL] [Abstract][Full Text] [Related]
8. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
9. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of anthracycline cardiotoxicity.
Mele D; Tocchetti CG; Pagliaro P; Madonna R; Novo G; Pepe A; Zito C; Maurea N; Spallarossa P
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e3-e11. PubMed ID: 27755237
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
[TBL] [Abstract][Full Text] [Related]
12. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
13. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection.
Madonna R; Cadeddu C; Deidda M; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Spallarossa P; Tocchetti CG; Zito C; Mercuro G
Heart Fail Rev; 2015 Sep; 20(5):621-31. PubMed ID: 26168714
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine in the prevention of anthracycline cardiotoxicity.
Corradi F; Paolini L; De Caterina R
Pharmacol Res; 2014 Jan; 79():88-102. PubMed ID: 24269342
[TBL] [Abstract][Full Text] [Related]
15. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e84-e92. PubMed ID: 27755246
[TBL] [Abstract][Full Text] [Related]
16. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
Saganelidze K; Kavtaradze N
Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of anthracycline cardiotoxicity].
Rossetti R
Suppl Tumori; 2004; 3(4):S117-9. PubMed ID: 15206234
[No Abstract] [Full Text] [Related]
18. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e55-e63. PubMed ID: 27755243
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline-dependent cardiotoxicity and extracellular matrix remodeling.
Nikitovic D; Juranek I; Wilks MF; Tzardi M; Tsatsakis A; Tzanakakis GN
Chest; 2014 Oct; 146(4):1123-1130. PubMed ID: 25288002
[TBL] [Abstract][Full Text] [Related]
20. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Vejpongsa P; Yeh ET
J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
